secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-09-06T23:59:59+00:00
Accession:  0001104659-24-097781
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics (GANX) enters $50M at-the-market equity offering with Oppenheimer
--------------------------------------------------------------------------------

- Equity Distribution Agreement allows sale of up to $50M in common stock via Oppenheimer as agent.
- Oppenheimer will receive a 3.0% commission on gross proceeds; company also reimburses certain expenses.
- Sales will be made under existing shelf registration statement (Form S-3, effective June 1, 2022).
- Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
- Shares offered through Nasdaq or other trading market; no escrow or trust arrangement for proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924097781/0001104659-24-097781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924097781/tm2423330d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-097781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer